Effects of High-and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator

被引：0
|
作者：
Tran, Jonathan Q. [1 ]
Hartung, Jeffrey P. [2 ]
Tompkins, Cindy-ann [3 ]
Frohna, Paul A. [3 ]
机构：
[1] Celgene Corp, Summit, NJ USA
[2] Receptos Inc, San Diego, CA USA
[3] Receptos Inc, Summit, NJ USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2016年 / 111卷
关键词：
D O I：
10.14309/00000434-201610001-00650
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
650
引用
下载
收藏
页码：S298 / S298
页数：1
相关论文
共 50 条
  • [31] The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
    Huwiler, Andrea
    Zangemeister-Wittke, Uwe
    PHARMACOLOGY & THERAPEUTICS, 2018, 185 : 34 - 49
  • [32] Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
    Cohen, Jeffrey A.
    Arnold, Douglas L.
    Comi, Giancarlo
    Bar-Or, Amit
    Gujrathi, Sheila
    Hartung, Jeffrey P.
    Cravets, Matt
    Olson, Allan
    Frohna, Paul A.
    Selmaj, Krzysztof W.
    LANCET NEUROLOGY, 2016, 15 (04): : 373 - 381
  • [33] Ponesimod, a selective sphingosine 1-phosphate (S1P1) receptor modulator for autoimmune diseases: review of clinical pharmacokinetics and drug disposition
    Dash, Ranjeet Prasad
    Rais, Rana
    Srinivas, Nuggehally R.
    XENOBIOTICA, 2018, 48 (05) : 442 - 451
  • [34] Species variation in sphingosine 1-phosphate receptor subtype 5 affects response to ozanimod in preclinical models of multiple sclerosis
    Selkirk, J.
    Yan, G.
    Ching, N.
    Biswas, S.
    Dines, K.
    Smith, S.
    Lopez, C.
    Ruiz, I.
    Hargreaves, R.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 309 - 309
  • [35] Development of high potency and highly selective ligands for Sphingosine 1-Phosphate Receptor
    Rosenberg, Adam
    Liu, Hui
    Tu, Zhude
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [36] Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
    Mehling, M.
    Johnson, T. A.
    Antel, J.
    Kappos, L.
    Bar-Or, A.
    NEUROLOGY, 2011, 76 (08) : S20 - S27
  • [37] Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo
    Hu, Yinghui
    Lee, Xinhua
    Ji, Benxiu
    Guckian, Kevin
    Apicco, Daniel
    Pepinsky, R. Blake
    Miller, Robert H.
    Mi, Sha
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2011, 48 (01) : 72 - 81
  • [38] The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis
    Al-Shamma, Hussien
    Lehmann-Bruinsma, Karin
    Carroll, Chris
    Solomon, Michelle
    Komori, H. Kiyomi
    Peyrin-Biroulet, Laurent
    Adams, John
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 369 (03): : 311 - 317
  • [39] Pharmacological Modulation of Peripheral T and B Lymphocytes by a Selective Sphingosine 1-Phosphate Receptor-1 Modulator
    Moberly, James B.
    Rohatagi, Shashank
    Zahir, Hamim
    Hsu, Ching
    Noveck, Robert J.
    Truitt, Kenneth E.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (07): : 996 - 1006
  • [40] Sphingosine 1-Phosphate Receptor Modulator FTY720 Suppresses Rat Experimental Autoimmune Prostatitis
    Zhang, Z. -Y.
    Zug, C.
    Schluesener, H. J.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2011, 73 (06) : 546 - 553
12345